Patients require baseline lipid profiles, cardiovascular risk assessment, and regular monitoring including weight tracking, lipid profile reassessment at 3-6 months and annually, blood pressure monitoring, and assessment of side effects throughout treatment
Source: New England Journal of Medicine Furthermore, the patients in the study who received semaglutide had a greater improvement with respect to cardiometabolic risk factors and reported a greater increase in physical functioning from baseline compared to the placebo group, so the supplement also improves metabolic (energy processing) and cardiovascular (heart) health
Eur J Neurosci 7 : 22942300
The fosgonimeton clinical history is not direct evidence about Dihexa, since the two compounds have different chemical structures and different pharmacokinetic profiles
Low blood sugar (hypoglycemia) is also a common side effect when used in people taking certain other diabetes treatments (like sulfonylureas or insulin) and can be serious